ENSYSCE BIOSCIENCES, INC. 2,280,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 620,000 Shares of Common Stock Warrants to Purchase up to 5,800,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • December 8th, 2022 • Ensysce Biosciences, Inc. • Pharmaceutical preparations
Contract Type FiledDecember 8th, 2022 Company IndustryEnsysce Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained in this Underwriting Agreement (the “Agreement”), to sell to you (the “Underwriter”), an aggregate of (i) 2,280,000 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 620,000 shares of Common Stock (the “Pre-Funded Warrant Shares”) and (iii) warrants (the “Firm Warrants”) to purchase up to an aggregate of 5,800,000 shares of Common Stock (the “Firm Warrant Shares”). The Firm Shares, the Pre-Funded Warrants, the Pre-Funded Warrant Shares, the Firm Warrants and the Firm Warrant Shares are collectively referred to as the “Firm Securities.” The Company also proposes to issue and sell to the Underwriter, upon the terms and conditions set forth herein, up to an additional (i) 342,000 shares of Common Stock (the “Option Shares”, a
ENSYSCE BIOSCIENCES, INC. [●] Shares of Common Stock Pre-Funded Warrants to Purchase up to [●] Shares of Common Stock Warrants to Purchase up to [●] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • December 1st, 2022 • Ensysce Biosciences, Inc. • Pharmaceutical preparations
Contract Type FiledDecember 1st, 2022 Company IndustryEnsysce Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained in this Underwriting Agreement (the “Agreement”), to sell to you (the “Underwriter”), an aggregate of (i) [●] shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of [●] shares of Common Stock (the “Pre-Funded Warrant Shares”) and (iii) warrants (the “Firm Warrants”) to purchase up to an aggregate of [●] shares of Common Stock (the “Firm Warrant Shares”). The Firm Shares, the Pre-Funded Warrants, the Pre-Funded Warrant Shares, the Firm Warrants and the Firm Warrant Shares are collectively referred to as the “Firm Securities.” The Company also proposes to issue and sell to the Underwriter, upon the terms and conditions set forth herein, up to an additional (i) [●] shares of Common Stock (the “Option Shares”, and together with the
2,000,000 Shares of Common Stock and 1,500,000 Warrants MILESTONE SCIENTIFIC INC. UNDERWRITING AGREEMENTUnderwriting Agreement • December 16th, 2016 • Milestone Scientific Inc. • Orthopedic, prosthetic & surgical appliances & supplies • New York
Contract Type FiledDecember 16th, 2016 Company Industry JurisdictionMilestone Scientific Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions contained herein, (this “Agreement”), to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom Maxim Group LLC (“Maxim”) is acting as Representative (the “Representative,” “you” or similar terminology), an aggregate of 2,000,000 shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and 1,500,000 warrants (the “Warrants”) with the right to purchase one share of Common Stock at an exercise price of $2.55 per share (together, “Securities”). The respective numbers of Securities to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 300,000 shares of Common Stock (the “Option Shares”) and/or up to an additional 225,000 Warrants (the “Optio
ONCOLYTICS BIOTECH INC. 4,250,000 Shares 1,700,000 Warrants UNDERWRITING AGREEMENTUnderwriting Agreement • November 18th, 2009 • Oncolytics Biotech Inc • Pharmaceutical preparations • New York
Contract Type FiledNovember 18th, 2009 Company Industry JurisdictionOncolytics Biotech Inc., an Alberta corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representative (the “Representative”), an aggregate of 4,250,000 units (the “Units”) of the Company (the “Underwritten Securities”), with each such Unit comprised of one of the Company’s common shares (the “Common Shares”), and 0.4 of one warrant to purchase Common Shares, with each whole warrant exercisable for one Common Share (each, a “Warrant” and collectively, the “Warrants”). The respective amounts of the Underwritten Securities to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 637,500 Common Shares (the “Option Shares”) and/or up to an additional 255,000 Warrants (